Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 6/20 | 0.42 |
| ▸ | KDR | P35968 | 6/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | RHEB | Q15382 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485185 | 0.81 | KMT2A (0.54) | EGFRERBB2PDE7AHPGDLMNA | |
| SCHEMBL3484543 | 0.80 | EGFR (0.49) | EGFRERBB2AURKAKDRCDK1 | |
| SCHEMBL3485042 | 0.79 | CASP1 (0.40) | PDE7AHPGDLMNAMAPT | |
| SCHEMBL3484991 | 0.75 | PARP1 (0.44) | HTR2APARP1 | |
| SCHEMBL3485033 | 0.74 | EGFR (0.49) | EGFRERBB2KDRCA12CA9 | |
| SCHEMBL3484193 | 0.74 | EGFR (0.49) | EGFRERBB2KDRCA12CA9 | |
| SCHEMBL3484676 | 0.74 | AHR (0.56) | EGFRERBB2 | |
| SCHEMBL3484789 | 0.72 | PDE7A (0.34) | PDE7ARHEBHPGDMEN1KMT2A | |
| SCHEMBL1964539 | 0.72 | CYP3A4 (0.56) | PDE7AHTR2ASLC6A4HPGDLMNA | |
| SCHEMBL27768766 | 0.71 | PDE7A (0.33) | PDE7ARHEBHTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | EGFR 13/4885ERBB2 1/4885AURKA 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.